Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda A breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda. Moderna's CEO revealed the promising five-year results. Orignial Source: https://www.foxbusiness.com/media/moderna-ceo-hails-breakthrough-mrna-cancer-vaccine-halves-melanoma-recurrence-risk-keytruda Previous article: Amazon’s Ring expands AI-powered network to help locate lost dogs Prev Next article: Restored Social Security benefits could get tax break under new bill Next
